Onychomycosis Market to Observe Impressive Growth During the Forecast Period (2022-2032), Evaluates DelveInsight | Key Companies – NovaBiotics Ltd, Hallux, Pfizer, GlaxoSmithKline, Blueberry

DelveInsight’s “Onychomycosis Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Onychomycosis, historical and forecasted epidemiology as well as the Onychomycosis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

To Know in detail about the Onychomycosis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Onychomycosis Market Forecast

Some of the key facts of the Onychomycosis Market Report: 

• The Onychomycosis market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
• In 2020, the total prevalent population of onychomycosis in 7MM markets was 93,633,252 cases, which are expected to rise during the forecast period (2022–2032)
• The total prevalent cases for onychomycosis were highest in the United States, which accounted for approximately 39% of the total prevalent cases
• Among the European countries, France had the highest prevalent population of onychomycosis with 11,369,288 cases, followed by Germany, which had a prevalent population of 10,053,740 in 2020. Spain accounted for the least number of cases in 2020
• Key Onychomycosis Companies: NovaBiotics Ltd, Hallux, Pfizer, GlaxoSmithKline, Blueberry Therapeutics, Hallux, AmtixBio Co., Ltd., Celtic Pharma, Hallux, Inc., Halcygen Pharma, SATO Pharmaceutical, Moberg Pharma AB, Polichem S.A., Hisamitsu Pharma, Nitric BioTherapeutics, and others
• Key Onychomycosis Therapies: Novexatin, HSG, AN2690, Albaconazole, BB2603-1, HSG, ATB1651, TDT067, Hallux Terbinafine, SUBA-itraconazole, SKX-16, MOB015B, P-3058, HTU-520 Patch, Terbinafine, and others
• The Onychomycosis epidemiology based on gender analyzed that no gender bias was observed in the case of onychomycosis
• The Onychomycosis market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Onychomycosis pipeline products will significantly revolutionize the Onychomycosis market dynamics.

Onychomycosis Overview

Onychomycosis, a fungal infection of the nail, is the most common nail infection worldwide, causing discoloration and thickening of the affected nail plate. Onychomycosis was initially thought to be caused by dermatophytes predominantly; however, new research has revealed that mixed infections and those caused by no dermatophyte molds (NDMs) are more prevalent than thought previously, especially in warmer climates.

Get a Free sample for the Onychomycosis Market Report 

https://www.delveinsight.com/sample-request/onychomycosis-market

Onychomycosis Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Onychomycosis Epidemiology Segmentation:

The Onychomycosis market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

• Total Prevalence of Onychomycosis
• Prevalent Cases of Onychomycosis by severity
• Gender-specific Prevalence of Onychomycosis
• Diagnosed Cases of Episodic and Chronic Onychomycosis

Download the report to understand which factors are driving Onychomycosis epidemiology trends @ Onychomycosis Epidemiology Forecast

Onychomycosis Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Onychomycosis market or expected to get launched during the study period. The analysis covers Onychomycosis market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Onychomycosis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Onychomycosis Therapies and Key Companies

• Novexatin: NovaBiotics Ltd
• HSG: Hallux
• AN2690: Pfizer
• Albaconazole: GlaxoSmithKline
• BB2603-1: Blueberry Therapeutics
• HSG: Hallux
• ATB1651: AmtixBio Co., Ltd.
• TDT067: Celtic Pharma
• Hallux Terbinafine: Hallux, Inc.
• SUBA-itraconazole: Halcygen Pharma
• SKX-16: SATO Pharmaceutical
• MOB015B: Moberg Pharma AB
• P-3058: Polichem S.A.
• HTU-520 Patch: Hisamitsu Pharma
• Terbinafine: Nitric BioTherapeutics

Discover more about therapies set to grab major Onychomycosis market share @ Onychomycosis Treatment Market

Onychomycosis Market Drivers

• Clinical Advancements
• Encouraging results of emerging therapies
• Wide acceptance of topical therapies

Onychomycosis Market Barriers

• Long duration of Treatment
• Discontinuation of drug development
• Issue of under diagnosis

Scope of the Onychomycosis Market Report

• Study Period: 2019–2032
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Onychomycosis Companies: NovaBiotics Ltd, Hallux, Pfizer, GlaxoSmithKline, Blueberry Therapeutics, Hallux, AmtixBio Co., Ltd., Celtic Pharma, Hallux, Inc., Halcygen Pharma, SATO Pharmaceutical, Moberg Pharma AB, Polichem S.A., Hisamitsu Pharma, Nitric BioTherapeutics, and others
• Key Onychomycosis Therapies: Novexatin, HSG, AN2690, Albaconazole, BB2603-1, HSG, ATB1651, TDT067, Hallux Terbinafine, SUBA-itraconazole, SKX-16, MOB015B, P-3058, HTU-520 Patch, Terbinafine, and others
• Onychomycosis Therapeutic Assessment: Onychomycosis current marketed and Onychomycosis emerging therapies
• Onychomycosis Market Dynamics: Onychomycosis market drivers and Onychomycosis market barriers 
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
• Onychomycosis Unmet Needs, KOL’s views, Analyst’s views, Onychomycosis Market Access and Reimbursement 

To know more about Onychomycosis companies working in the treatment market, visit @ Onychomycosis Clinical Trials and Therapeutic Assessment

Table of Contents 

1. Onychomycosis Market Report Introduction

2. Executive Summary for Onychomycosis

3. SWOT analysis of Onychomycosis

4. Onychomycosis Patient Share (%) Overview at a Glance

5. Onychomycosis Market Overview at a Glance

6. Onychomycosis Disease Background and Overview

7. Onychomycosis Epidemiology and Patient Population

8. Country-Specific Patient Population of Onychomycosis 

9. Onychomycosis Current Treatment and Medical Practices

10. Onychomycosis Unmet Needs

11. Onychomycosis Emerging Therapies

12. Onychomycosis Market Outlook

13. Country-Wise Onychomycosis Market Analysis (2019–2032)

14. Onychomycosis Market Access and Reimbursement of Therapies

15. Onychomycosis Market Drivers

16. Onychomycosis Market Barriers

17.  Onychomycosis Appendix

18. Onychomycosis Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services